New hope for advanced GI cancers: first human trial of 7MW4911 begins

NCT ID NCT07216560

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests a new drug called 7MW4911 in people with advanced colorectal or other gastrointestinal cancers that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works. About 200 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GI CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hematology Oncology Associates of the Treasure Coast

    RECRUITING

    Port Saint Lucie, Florida, 34952, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START

    RECRUITING

    Long Island City, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Moutain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.